Clinical Trial Detail

NCT ID NCT02353715
Title Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Duke University
Indications

prostate adenocarcinoma

Therapies

Abiraterone

Enzalutamide

Sipuleucel-T

Age Groups: adult

No variant requirements are available.